Viewing Study NCT00132639



Ignite Creation Date: 2024-05-05 @ 11:47 AM
Last Modification Date: 2024-10-26 @ 9:13 AM
Study NCT ID: NCT00132639
Status: COMPLETED
Last Update Posted: 2016-09-22
First Post: 2005-08-19

Brief Title: Study of Preoperative Docetaxel or Cisplatin CDDP Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer NSCLC
Sponsor: Haruhiko Fukuda
Organization: Japan Clinical Oncology Group

Study Overview

Official Title: Randomized Phase II Study of the Induction Chemotherapy With Docetaxel Alone vs CDDP Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer JCOG 0204-MF
Status: COMPLETED
Status Verified Date: 2016-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of the preoperative docetaxel and docetaxel-cisplatin combination in c-stage IBII NSCLC and select the optimal preoperative therapy for phase III trials
Detailed Description: Preoperative chemotherapy has substantial theoretical advantage Several controlled trials are under way in early stage clinical stage IB-II nonsmall cell lung cancer NSCLC In each trial platinum-based doublet chemotherapy is employed Although platinum-based doublet is the treatment of choice for advanced NSCLC riskbenefit balance might well be different in earlier stages There have been no prospective randomized trials to choose an optimal preoperative chemotherapy in early stage NSCLC

Comparison Preoperative cisplatin-docetaxel combination versus docetaxel monotherapy in clinical stage IBII NSCLC

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
C000000032 None None None